The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the largest U.S. corporations. For

fiscal Fiscal usually refers to government finance. In this context, it may refer to: Economics * Fiscal policy, use of government expenditure to influence economic development * Fiscal policy debate * Fiscal adjustment, a reduction in the government pr ...

2021, it had a total revenue of $46.4 billion. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS,

cardiovascular disease Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. CVD includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack). Other CVDs include stroke, h ...

, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. BMS's primary

research and development Research and development (R&D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existi ...

(R&D) sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton),

Summit, New Jersey Summit is a city in Union County, in the U.S. state of New Jersey. The city is located on a ridge in northern- central New Jersey, within the Raritan Valley and Rahway Valley regions in the New York metropolitan area. At the 2010 United Sta ...

, formerly HQ of Celgene,

New Brunswick, New Jersey New Brunswick is a city (New Jersey), city in and the county seat, seat of government of Middlesex County, New Jersey, Middlesex County, in the U.S. state of New Jersey.Redwood City, California, and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts, East Syracuse, New York, Braine-l'Alleud, Belgium, Tokyo, Japan, Bangalore, India, and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).

History

Squibb

The Squibb corporation was founded in 1858 by

Edward Robinson Squibb Edward Robinson Squibb (July 4, 1819October 25, 1900) was a medical doctor, a leading American inventor, and manufacturer of pharmaceutics who founded E. R. Squibb and Sons, which eventually became part of the modern pharmaceutical giant Bristol ...

in Brooklyn, New York. Squibb was known as an advocate of quality control and high purity standards early within the pharmaceutical industry. He went on to self-publish an alternative to the U.S. Pharmacopeia titled ''Squibb's Ephemeris of Materia Medica,'' after failing to convince the American Medical Association to incorporate higher purity standards. ''Materia Medica'', Squibb products, and Edward Squibb's opinion on the fundamentals of pharmacy are found in many medical papers of the late 1800s. The ''

American Journal of Pharmacy American(s) may refer to: * American, something of, from, or related to the United States of America, commonly known as the "United States" or "America" ** Americans, citizens and nationals of the United States of America ** American ancestry, p ...

'' published more than one hundred papers of Squibb's research surrounding the industry. The sons of Edward Squibb sold the company to Lowell M. Palmer and Theodore Weicker in 1905, who incorporated the company. Around this time, the Squibb logo was developed, which represented the company's products of "uniformity, purity, efficacy, and reliability based on research." Squibb Corporation served as a major supplier of medical goods to the Union Army during the American Civil War, providing portable medical kits containing morphine, surgical anesthetics, and quinine for the treatment of malaria (which was endemic in most of the Eastern United States at that time). In 1944, Squibb opened the world's largest penicillin plant in

William McLaren Bristol William McLaren Bristol (28July 18601935) was one of the two co-founders of Bristol-Myers, now part of Bristol-Myers Squibb. Myers and Bristol founded the company that would evolve into an international pharmaceutical giant in Bristol's birthplac ...

and

John Ripley Myers John Ripley Myers (October 8, 1864 – December 22, 1899) was a co-founder (along with William McLaren Bristol) of the pharmaceutical company Bristol-Myers. Life John Ripley Myers was born in Cleveland, Ohio, on October 8, 1864. His father was ...

purchased the Clinton Pharmaceutical company of

Clinton Clinton is an English toponymic surname, indicating one's ancestors came from English places called Glympton or Glinton.Hanks, P. & Hodges, F. ''A Dictionary of Surnames''. Oxford University Press, 1988 Clinton has frequently been used as a given ...

, New York. In May 1898, they decided to rename it Bristol, Myers and Company. Following Myers' death in 1899, Bristol changed the name to the Bristol-Myers Corporation. During the 1890s, the company introduced its first nationally recognized product Sal Hepatica, a laxative mineral salt, followed by Ipana toothpaste in 1901.Bert Rosenbloom, ''Marketing Channels''
Bristol-Myers Squibb
, 2011, page 609 Other divisions were Clairol (hair colors and haircare) and Drackett (household products such as Windex and Drano). In 1943, Bristol-Myers acquired Cheplin Biological Laboratories, a producer of

acidophilus milk ''Lactobacillus acidophilus'' ( New Latin 'acid-loving milk-bacillus') is a rod-shaped, Gram-positive, homofermentative, anaerobic microbe first isolated from infant feces in the year 1900. The species is most commonly found in humans, specific ...

in East Syracuse, New York, and converted the plant to produce

penicillin Penicillins (P, PCN or PEN) are a group of β-lactam antibiotics originally obtained from ''Penicillium'' moulds, principally '' P. chrysogenum'' and '' P. rubens''. Most penicillins in clinical use are synthesised by P. chrysogenum using ...

for the World War II Allied forces. After the war, the company renamed the plant

Bristol Laboratories The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...

in 1945 and entered the civilian antibiotics market, where it faced competition from Squibb. Penicillin production at the East Syracuse plant ended in 2005, when it became less expensive to produce overseas. As of 2010, the facility was used for the manufacturing process development and production of other biologic medicines for clinical trials and commercial use.

Merger

In 1989, Bristol-Myers and Squibb merged and became Bristol-Myers Squibb. In 1999, then-U.S. President Bill Clinton awarded Bristol-Myers Squibb the National Medal of Technology, the nation's highest recognition for technological achievement, "for extending, and enhancing human life through innovative pharmaceutical research and development and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry."

2000 to 2010

In 2002, the company was involved in a lawsuit of illegally maintaining a monopoly on Taxol, its cancer treatment, and it was again sued for the antitrust lawsuit 5 years later, which cost the company $125 million for settlement. Also in 2002, Bristol-Myers Squibb was involved in an accounting scandal that resulted in a significant restatement of revenues from 1999 to 2001. The restatement was the result of an improper booking of sales related to " channel stuffing" as the practice of offering excess inventory to customers to create higher sales numbers. The company has since settled with the United States Department of Justice and

Securities and Exchange Commission The U.S. Securities and Exchange Commission (SEC) is an independent agency of the United States federal government, created in the aftermath of the Wall Street Crash of 1929. The primary purpose of the SEC is to enforce the law against market ...

, agreeing to pay $150 million, while neither admitting nor denying guilt. On October 24, 2002, Bristol-Myers Squibb Co. restated earnings downward for parts of 2000 and 2001, while revising this year's earnings upward because of its massive inventory backlog imbroglio that spurred two government investigations. On March 15, 2004, Bristol-Myers Squibb Co. adjusted upward its fourth-quarter and full-year 2003 results after reversing an earlier decision about how to deal with accounting errors made in prior years. As part of a deferred prosecution agreement, the company was placed under the oversight of a monitor appointed by the U.S. attorney in w Jersey. In addition, the former head of the Pharma group, Richard Lane, and the ex-CFO, Fred Schiff, were indicted for federal securities violations. In July 2006, an investigation of the company was made public, and the FBI raided the company's corporate offices. The investigation centered on the distribution of Plavix and charges of collusion. On September 12, 2006, the monitor, former Federal Judge Frederick B. Lacey, urged the company to remove then-CEO Peter Dolan over the Plavix dispute. Later that day, BMS announced that Dolan would indeed step down. The deferred prosecution agreement expired in June 2007 and the Department of Justice did not take any further legal action against the company for matters covered by the DPA. Under CEO Jim Cornelius, who was CEO following Dolan until May 2010, all executives involved in the "channel-stuffing" and generic competition scandals have since left the company. In 2009, the company began a major restructuring focusing on the pharmaceutical business and biologic products, along with productivity initiatives and cost-cutting and streamlining business operations through a multiyear program of on-going layoffs. This was part of a business strategy launched in 2007 to transform the company from a large, diversified pharmaceutical company to a specialty biopharma company, which also included the closure of half of their manufacturing facilities. As another cost-cutting measure, Bristol-Myers Squibb also reduced health-care subsidies for retirees and plans to freeze their pension plan at the end of 2009. BMS is a ''Fortune'' 500 Company (#114 in 2010 list). ''Newsweek's ''2009 Green Ranking recognized Bristol-Myers Squibb as eighth among 500 of the largest United States corporations. Also, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.

Lamberto Andreotti Lamberto Andreotti (born 6 July 1950) is an Italian businessman. He is currently executive chairman of the board of Bristol Myers Squibb. Biography Early life Andreotti was born in Rome, Italy, in 1950, the son of Italian Senator and Presiden ...

was named

CEO A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO) or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization especially ...

in 2010; he had previously served as "president and COO responsible for all pharmaceutical operations worldwide."

2010 onward

Bristol Myers Squibb, Moreton, Wirral - IMG 0369

In 2010, Lou Schmukler joined Bristol-Myers Squibb as the president of global product development and design. Schmukler led the team that completed the company's strategic transformation to a specialty biopharmaceutical company that had begun in 2007. As of 2011, the company had a dozen manufacturing facilities and six product development sites. Citing major developments and a market capitalization of US$87 billion and stock appreciation of 61.4%, Bristol-Myers Squibb was ranked as the best drug company of 2013 by ''Forbes'' magazine. In December 2014, the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot be removed or have not responded to previous drug therapies. In February 2015, the company initiated a research partnership with Rigel Pharmaceuticals which could generate more than $339 million. In March, the company obtained an exclusive opportunity to both licence and commercialise PROSTVAC,

Bavarian Nordic Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, wit ...

's phase III prostate-specific antigen targeting cancer immunotherapy. Bavarian Nordic would receive an upfront payment of $60 million and incremental payments up to $230 million, if the overall survival of test patients exceeds that seen in Phase II tests. Bavarian could also receive milestone payments of between $110 million and $495 million, dependent on regulatory authorization, and these payments have the potential to total up to $975 million. In May 2015, Dr. Giovanni Caforio became CEO of the company; Caforio was formerly the company's COO and succeeded Andreotti upon his retirement. Andreotti subsequently succeeded James Cornelius as

executive chairman The chairperson, also chairman, chairwoman or chair, is the presiding officer of an organized group such as a board, committee, or deliberative assembly. The person holding the office, who is typically elected or appointed by members of the grou ...

upon his retirement. In late February 2017, '' The Wall Street Journal'' and ''

Fortune Fortune may refer to: General * Fortuna or Fortune, the Roman goddess of luck * Luck * Wealth * Fortune, a prediction made in fortune-telling * Fortune, in a fortune cookie Arts and entertainment Film and television * ''The Fortune'' (1931 film) ...

'', among others, reported that activist investor Carl Icahn had taken a stake in the company, signaling a potential future takeover from the likes of Gilead Sciences. In April 2018, the company reported net income of $1.5 billion, or 91 cents per share, for the first quarter of the year, thanks to the increased sales of their cancer drug Opdivo.

Corporate acquisitions and divestments as Bristol Myers Squibb

In August 2009, during a major restructuring activity, BMS acquired the biotechnology firm

Medarex Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. ...

as part of the company's "String of Pearls" strategy of alliances, partnerships, and acquisitions. In November 2009, Bristol Myers Squibb announced that it was "splitting off" Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson. According to Bristol Myers Squibb, this move was expected to further sharpen the company's focus on biopharmaceuticals. In October 2010, the company acquired ZymoGenetics, securing an existing product, as well as pipeline assets in hepatitis C, cancer, and other therapeutic areas. Bristol Myers Squibb agreed to pay around $2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead/

Pharmasset Pharmasset Inc. was a pharmaceutical company based in Princeton, New Jersey in the United States. The company develops antiviral drugs for HIV (including racivir), hepatitis B (including clevudine, marketed as Levovir), and hepatitis C. In N ...

to produce

hepatitis C Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, a ...

drugs. The settlement will be finished in 2 months for its Inhibitex's shareholders acceptance of 126% premium price of its price over the previous 20 trading days ended on January 6. On June 29, BMS extended its portfolio of diabetes treatments when it agreed to buy Amylin Pharmaceuticals for around in cash and pay to Eli Lilly to cover Amylin's debt and its outstanding collaboration-related obligations. AstraZeneca, which already collaborated on several diabetes treatments with BMS, agreed to pay US$3.4 billion in cash for the right to continue development of Amylin's products. Two years later, the company divested Amylin to AstraZeneca. In April 2014, BMS announced its acquisition of iPierian for up to $725 million. In February 2015, the company acquired Flexus Biosciences for $1.25 billion. As part of this deal, BMS will gain full rights to Flexus' lead small molecule IDO1-inhibitor, F001287. In November, the company acquired the

drug developer Cardioxyl for up to $2.075 billion. The deal strengthens the BMS' critical pipelines with the phase II candidate for acute decompensated heart failure,

CXL-1427 Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitroxyl don ...

. In March 2016, the company announced it would acquire Padlock Therapeutics for up to $600 million. In early July, the company announced it would acquire Cormorant Pharmaceuticals for $520 million, boosting BMS' oncology offering through Cormorants monoclonal antibody targeted against interleukin-8. In August 2017 the company acquired IFM Therapeutics for $300 million upfront, with contingency payments of $1.01 billion due on certain milestones – allowing BMS to better compete against

Merck & Co Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp ...

's cancer rival treatment, Keytruda. In early January 2019, the company announced it would acquire Celgene (NASDAQ:CELG) for $74 billion ($95 billion including debt), in a deal that would become the largest pharmaceutical-company acquisition ever. The Celgene acquisition aimed to be a refresher to the company's pipeline, helping to overcome from declining sales of Opdivo relative to competitor Keytruda. Under the terms of the deal, Celgene shareholders would receive one BMS share as well as $50 in cash for each Celgene share held, valuing Celgene at $102.43 a share; representing a 54% premium to the previous days closing price. Investor opposition to this acquisition, leading into an April 12 shareholder vote, appeared when BMS's second-largest investor, Wellington Management, voiced its opposition, followed by investor Starboard Value. In April 2019 BMS announced that 75% of its shareholders voted to approve the pending merger with Celgene. Transaction to close in the third quarter of 2019, subject to regulatory approvals. Newly issued BMS shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol 'BMYRT'. The strategic divestment of the company's consumer health business, UPSA, to Taisho completed in 2019. UPSA focused product delivery on France and the rest of Europe. As early as 2005, the company had divested individual consumer products, and its US- and Canada-focused consumer products business. In August, the Amgen announced it would acquire the

Otezla Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. It may also be useful for other immune system-related inflammatory diseases. The drug acts as a se ...

drug programme from Celgene for $13.4 billion, as part of Celgene and BMS's merger deal. In February 2020, BMS and partner Biomotiv launched a new company called Anteros Pharmaceuticals, which focuses on creating inflammation and fibrosis medicines. In August, the business announced it would acquire Forbius and its TGF-beta 1 &

TGF-beta 3 Transforming growth factor beta (TGF-β) is a multifunctional cytokine belonging to the transforming growth factor superfamily that includes three different mammalian isoforms (TGF-β 1 to 3, HGNC symbols TGFB1, TGFB2, TGFB3) and many other sign ...

inhibitors. In October, BMS announced it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM), and the development of two key treatments: danicamtiv (MYK-491) and MYK-224. In June 2022, BMS announced it would acquire

Turning Point Therapeutics Turning is a machining process in which a cutting tool, typically a non-rotary tool bit, describes a helix toolpath by moving more or less linearly while the workpiece rotates. Usually the term "turning" is reserved for the generation o ...

Inc for $4.1 billion in cash ($76 per share, a 122.5% premium to its last closing price), helping to boost its compliment of cancer drugs, specifically repotrectinib.

List of mergers and acquisitions

The following is an illustration of the company's major mergers and acquisitions and historical predecessors: *Bristol-Myers Squibb (Formed by the merger of Squibb Corporation (Est 1858) and Bristol-Myers (Est 1887)) **

Adnexus Therapeutics In anatomy, adnexa (plural) refers to the appendages of an organ. The term ''adnexa'' is from the Latin word ''adnexa'' (appendages). More specifically, it can refer to: * Adnexa of eye (accessory visual structures) * Adnexa of skin (skin appenda ...

** ConvaTec ** Kosan Biosciences **

(Acq 2009) ** ZymoGenetics (Acq 2010) **

Amira Pharmaceuticals Amira, Ameerah, or Ameera may refer to: Arts and entertainment * ''Amira'' (album), by Amira Willighagen, 2014 * ''Amira'' (film), a 2021 Jordanian film People * Amira (name), an Arabic and Hebrew female given name * Amira (singer), American sin ...

** Inhibitex Inc (Acq 2012) ** Amylin Pharmaceuticals (Acq 2012 jointly with AstraZeneca) ** iPierian (Acq 2014) **

Flexus Biosciences (English: Travelcard; formerly named Flexus) is an electronic ticket system that was introduced on all public transport in Greater Oslo, in 2009 using Thales technology. The system may eventually replace all paper tickets on trips with Ruter ( ...

(Acq 2015) ** Cardioxyl (Acq 2015) ** Padlock Therapeutics (Acq 2016) **

Cormorant Pharmaceuticals Phalacrocoracidae is a family of approximately 40 species of aquatic birds commonly known as cormorants and shags. Several different classifications of the family have been proposed, but in 2021 the IOC adopted a consensus taxonomy of seven ge ...

(Acq 2016) ** IFM Therapeutics (Acq 2017) ** Celgene (Acq 2019) *** Signal Pharmaceuticals, Inc (Acq 2000) *** Anthrogenesis (Acq 2002) *** Pharmion Corporation (Acq 2008) *** Gloucester Pharmaceuticals (Acq 2009) *** Abraxis BioScience Inc (Acq 2010) *** Avila Therapeutics, Inc (Acq 2012) *** Quanticel (Acq 2015) *** Receptos (Acq 2015) *** EngMab AG (Acq 2016) *** Delinia (Acq 2017) *** Impact Biomedicines (Acq 2018) ***

Juno Therapeutics Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Instit ...

(Acq 2018) **** AbVitro (Acq 2016) **** RedoxTherapies (Acq 2016) ** Forbius (Acq 2020) ** MyoKardia (Acq 2020) ** Turning Point Therapeutics (Acq 2022)

Finances

For the fiscal year 2018,Bristol Myers Squibb reported earnings of US$1.007 billion, with an annual revenue of US$20.776 billion, an increase of 6.9% over the previous fiscal cycle. Bristol-Myers Squibb's shares traded at over $55 per share, and its market capitalization was valued at over US$81.6 billion in October 2018. In 2018, 85% of the company's revenues came from just five products. In 2018, Bristol-Myers Squibb spent 36% of its total revenue on R&D expenses. Bristol-Myers Squibb ranked 145th on the

Fortune 500 The ''Fortune'' 500 is an annual list compiled and published by ''Fortune'' magazine that ranks 500 of the largest United States corporations by total revenue for their respective fiscal years. The list includes publicly held companies, along ...

list of the largest United States corporations by revenue in 2018.

Carbon footprint

Bristol Myers Squibb reported Total CO2e emissions (Direct + Indirect) for the twelve months ending 31 December 2020 at 278 Kt (-6 /-2.1% y-o-y).Alt URL
/ref> The company aims to become net neutral carbon by 2040.

Pharmaceuticals

The following is a list of key pharmaceutical products: ''Cardiovascular diseases'' *Avalide ( irbesartan/ hydrochlorothiazide) – comarketed with Sanofi *Avapro ( irbesartan) – comarketed with Sanofi *Coumadin ( warfarin) *Eliquis ( apixaban) – comarketed with Pfizer *Plavix ( clopidogrel) – comarketed with Sanofi *Pravachol ( pravastatin) ''Diabetes mellitus'' *Bydureon ( exenatide extended-release) – marketed by BMS only in some countries *Byetta ( exenatide) – marketed by BMS only in some countries, such as Russian Federation *Farxiga/Forxiga ( dapagliflozin) *Glucophage ( metformin) – marketed by BMS only in USA *Glucophage XR ( metformin extended release) – marketed by BMS only in USA *Glucovance ( Glyburide/metformin) – marketed by BMS only in USA *Kombiglyze XR/Komboglyze ( saxagliptin/ metformin extended release) – comarketed with AstraZeneca *Onglyza ( saxagliptin) – comarketed with AstraZeneca ''Infectious diseases, including HIV infection and associated conditions'' * Atripla (

efavirenz Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlest ...

/ emtricitabine/

tenofovir disoproxil fumarate Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for preven ...

) – comarketed with Gilead Sciences *Azactam ( aztreonam) *Baraclude ( entecavir) *Daklinza ( daclatasvir) *Evotaz ( atazanavir/cobicistat) *Megace ( megestrol acetate) *Reyataz ( atazanavir) *Sustiva/Stocrin (

) *Videx ( didanosine) *Videx EC ( didanosine delayed-release) *Zerit ( stavudine) ''Inflammatory disorders'' *Kenalog-10 ( triamcinolone acetonide) *Kenalog-40 (triamcinolone acetonide) ''Oncology'' *Abecma ( idecabtagene vicleucel) *BiCNU (

carmustine Carmustine, sold under the brand name BiCNU among others, is a medication used mainly for chemotherapy. It is a nitrogen mustard β-chloro- nitrosourea compound used as an alkylating agent. Description Carmustine is an orange-yellow solid medica ...

) *Breyanzi (

lisocabtagene maraleucel Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat large B-cell lymphoma. Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune sy ...

) *CeeNU ( lomustine) *Droxia/Hydrea ( hydroxycarbamide) *Empliciti ( Elotuzumab) *Erbitux (

cetuximab Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal an ...

) *Etopophos ( etoposide) *Ixempra ( ixabepilone) *Lysodren ( mitotane) *Megace ( megestrol acetate) *Opdivo ( nivolumab) is a programmed death receptor blocking antibody used for the treatment of unresectable or metastatic melanoma and metastatic squamous non-small-cell lung carcinoma. In contrast to traditional chemotherapies and targeted anti-cancer therapies, which exert their effects by direct cytotoxic or tumor growth inhibition, nivolumab acts by inducing the immune system to attack the tumor. *Sprycel ( dasatinib) *Taxol ( paclitaxel). At one time, BMS held the solitary contract to harvest the bark of endangered

yew Yew is a common name given to various species of trees. It is most prominently given to any of various coniferous trees and shrubs in the genus ''Taxus'': * European yew or common yew (''Taxus baccata'') * Pacific yew or western yew (''Taxus br ...

trees on United States territory for the manufacture of chemotherapy drug paclitaxel (Taxol). Current paclitaxel production comes from renewable sources. BMS also held the original paclitaxel license, but there are now multiple generic producers. *Vumon (

teniposide Teniposide (trade name Vumon) is a chemotherapeutic medication used in the treatment of childhood acute lymphocytic leukemia (ALL), Hodgkin's lymphoma, certain brain tumours, and other types of cancer. It is in a class of drugs known as podophyllot ...

) *Yervoy ( ipilimumab) ''Psychiatry'' *Abilify ( aripiprazole comarketed with Otsuka Pharmaceutical) ''Rheumatic disorders'' *Orencia ( abatacept) ''Transplant rejection'' *Nulojix ( belatacept)

Out of production

* Sal Hepatica * Ipana

Divested brands

(Former Bristol-Myers brands, now divested) *

Bufferin Aspirin, also known as acetylsalicylic acid (ASA), is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, fever, and/or inflammation, and as an antithrombotic. Specific inflammatory conditions which aspirin is used to treat inc ...

Excedrin Aspirin(acetylsalicylic acid) / paracetamol(acetaminophen) / caffeine is a combination drug for the treatment of pain, especially tension headache and migraine. It is sold in the US under the trade names Goody's Powder and Excedrin, although no ...

* Ban Deodorant *Vitalis (hair tonic) *Ammens (medicated powder) *Final Net (hair spray) *Comtrex (cold relief capsules) * Keri (lotion)

Products under development

The following is a selective list of investigational products under development, as of 2015: * Beclabuvir (BMS-791325) – phase III *

BMS-906024 BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society The American Chemical Society (ACS) is a scientific society based in the United States that s ...

– phase I *

BMS-955176 BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T ...

– phase II *

Brivanib alaninate Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called '' ...

(BMS-582664) – development terminated * Elotuzumab (BMS-901608) – phase III * Fostemsavir (BMS-663068) – approved in the United States in July 2020 *

Lirilumab Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. Clinical trials A phase 2 clinical trial for acute m ...

(BMS-986015) *

Lulizumab pegol Lulizumab pegol (INN; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.

(BMS-931699) – phase II

Public-private engagement

Bristol-Myers Squibb engages with the public and private sectors in a variety of settings including to promote

, academic funding, event sponsorship,

philanthropy Philanthropy is a form of altruism that consists of "private initiatives, for the Public good (economics), public good, focusing on quality of life". Philanthropy contrasts with business initiatives, which are private initiatives for private goo ...

, and political lobbying.

Academia and education

* Institute for Advanced Study - Gift matching and direct donor. * Mentoring in IBD - Sponsor. * Northern Ontario School of Medicine (NOSM) - Donor. * Population Health Research Institute (PHRI) at McMaster University Medical School - Partner. * University of Toronto - Donor. * University of Washington - Donor.

Conferences and events

* Women in Medicine Summit - Sponsor. * World Neuroscience Innovation Forum - Sponsor.

Healthcare

* Centre for Addiction and Mental Health (CAMH) - Donor. * Princess Margaret Cancer Centre (PMCC) - Foundation donor and sponsor for the PMCC Conference. * Scarborough Health Network (SHN) - Donor to the Scarborough Health Foundation. *

SickKids The Hospital for Sick Children (HSC), corporately branded as SickKids, is a major pediatric teaching hospital located on University Avenue in Toronto, Ontario, Canada. Affiliated with the Faculty of Medicine of the University of Toronto, the hospi ...

- Donor to the SickKids Foundation. * Sinai Health System - Donor to the Sinai Health Foundation. *

Sunnybrook Health Sciences Centre Sunnybrook Health Sciences Centre (SHSC), commonly known as Sunnybrook Hospital or simply Sunnybrook, is an academic health science centre An academic medical centre (AMC), variously also known as academic health science centre, academic healt ...

- Donor.

Media

* National Geographic Society - Donor. * National Press Foundation - Funder.

Medical societies

* American Society of Hematology (ASH) - Corporate supporter. *

Arthritis Society Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, swelling, and decreased range of motion of the affected joints. In some ...

- National corporate partner. * Canadian Society of Internal Medicine - Sponsor. * European Society of Cardiology - Sponsor. * Spanish Cardiac Society - Partner.

Political lobbying

BIOTECanada BIOTECanada, or the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international ...

- Member company. BIOTECanada lobbies the Canadian government for policies favourable to the pharmaceutical industry. * Innovative Medicines Canada - Member. * International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) - Member. * National Health Council - Member. *

National Pharmaceutical Council National may refer to: Common uses * Nation or country ** Nationality – a ''national'' is a person who is subject to a nation, regardless of whether the person has full rights as a citizen Places in the United States * National, Maryland, ce ...

- Member. *

Personalized Medicine Coalition Personalization (broadly known as customization) consists of tailoring a service or a product to accommodate specific individuals, sometimes tied to groups or segments of individuals. A wide variety of organizations use personalization to improv ...

- Member. * Pharmaceutical Advertising Advisory Board - Client. * Pharmaceutical Research and Manufacturers of America - Member. * Research!America - Member.

Professional associations

* Canadian Association of Emergency Physicians (CAEP) - Corporate partner. *

Canadian Rheumatology Association Canadians (french: Canadiens) are people identified with the country of Canada. This connection may be residential, legal, historical or cultural. For most Canadians, many (or all) of these connections exist and are collectively the source of ...

(CRA) - Corporate sponsor. * CARE Faculty - Sponsor. CARE is a Canadian coalition of medical specialists based in Oakville, Ontario. BMS was a sponsor for their 2021 Winter Hematology Update event. *

Colorectal Cancer Canada The large intestine, also known as the large bowel, is the last part of the gastrointestinal tract and of the digestive system in tetrapods. Water is absorbed here and the remaining waste material is stored in the rectum as feces before being rem ...

(CRC) - Sponsor. * Health Products Stewardship Association - Member.

Research and development

Lung Health Foundation The lungs are the primary organs of the respiratory system in humans and most other animals, including some snails and a small number of fish. In mammals and most other vertebrates, two lungs are located near the backbone on either side of t ...

- Partner. * Multiple Sclerosis International Federation - Partner. *

Pinnacle Research Group A pinnacle is an architecture, architectural element originally forming the cap or crown of a buttress or small Turret (architecture), turret, but afterwards used on parapets at the corners of towers and in many other situations. The pinnacle lo ...

- Sponsor. *

Radcliffe Cardiology Radcliffe or Radcliff may refer to: Places * Radcliffe Line, a border between India and Pakistan United Kingdom * Radcliffe, Greater Manchester ** Radcliffe Tower, the remains of a medieval manor house in the town ** Radcliffe tram stop * Ra ...

- Industry partner.

Scandals

Bristol-Myers Squibb, Johns Hopkins University and the

Rockefeller Foundation The Rockefeller Foundation is an American private foundation and philanthropic medical research and arts funding organization based at 420 Fifth Avenue, New York City. The second-oldest major philanthropic institution in America, after the Carneg ...

are currently the subject of a $1 billion lawsuit from

Guatemala Guatemala ( ; ), officially the Republic of Guatemala ( es, República de Guatemala, links=no), is a country in Central America. It is bordered to the north and west by Mexico; to the northeast by Belize and the Caribbean; to the east by H ...

for "roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with

syphilis Syphilis () is a sexually transmitted infection caused by the bacterium ''Treponema pallidum'' subspecies ''pallidum''. The signs and symptoms of syphilis vary depending in which of the four stages it presents (primary, secondary, latent, an ...

". A previous suit against the United States government was dismissed in 2011 for the

Guatemala syphilis experiments The Guatemala syphilis experiments were United States-led human experiments conducted in Guatemala from 1946 to 1948. The experiments were led by physician John Charles Cutler, who also participated in the late stages of the Tuskegee syphilis exp ...

when a judge determined that the U.S. government could not be held liable for actions committed outside of the U.S.

Notes and references

External links

*
Bristol-Myers Squibb worldwide locations

Bristol-Myers Squibb Influence and Lobbying Summary – Opensecrets.org
{{Authority control 1920s initial public offerings American companies established in 1887 Manufacturing companies based in New York City Multinational companies based in New York City Biotechnology companies of the United States Companies listed on the New York Stock Exchange Pharmaceutical companies established in 1887 Pharmaceutical companies of the United States Publicly traded companies based in New York City 1887 establishments in New York (state) National Medal of Technology recipients Orphan drug companies Life sciences industry